- Home
- AMBO vs APRE Comparison
AMBO vs APRE Comparison
Compare AMBO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- APRE
- Stock Information
- Founded
- AMBO 2000
- APRE 2006
- Country
- AMBO United States
- APRE United States
- Employees
- AMBO N/A
- APRE N/A
- Industry
- AMBO Other Consumer Services
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMBO Real Estate
- APRE Health Care
- Exchange
- AMBO Nasdaq
- APRE Nasdaq
- Market Cap
- AMBO 7.1M
- APRE 8.4M
- IPO Year
- AMBO 2010
- APRE 2019
- Fundamental
- Price
- AMBO $2.56
- APRE $1.62
- Analyst Decision
- AMBO
- APRE Strong Buy
- Analyst Count
- AMBO 0
- APRE 2
- Target Price
- AMBO N/A
- APRE $15.50
- AVG Volume (30 Days)
- AMBO 11.6K
- APRE 29.8K
- Earning Date
- AMBO 12-30-2024
- APRE 05-13-2025
- Dividend Yield
- AMBO N/A
- APRE N/A
- EPS Growth
- AMBO N/A
- APRE N/A
- EPS
- AMBO 0.11
- APRE N/A
- Revenue
- AMBO $9,392,000.00
- APRE $1,502,581.00
- Revenue This Year
- AMBO N/A
- APRE N/A
- Revenue Next Year
- AMBO N/A
- APRE N/A
- P/E Ratio
- AMBO $23.56
- APRE N/A
- Revenue Growth
- AMBO 2.50
- APRE 157.63
- 52 Week Low
- AMBO $1.00
- APRE $1.41
- 52 Week High
- AMBO $5.55
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- AMBO 47.49
- APRE 36.93
- Support Level
- AMBO $2.45
- APRE $1.41
- Resistance Level
- AMBO $3.14
- APRE $1.59
- Average True Range (ATR)
- AMBO 0.30
- APRE 0.11
- MACD
- AMBO -0.02
- APRE 0.03
- Stochastic Oscillator
- AMBO 19.86
- APRE 48.04
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.